Sydney, 20 August 2018: Noxopharm (ASX:NOX) today announces that the trade mark, VeyondaTM, has been approved in Australia as part of a world-wide application. NOX66 is due to embark next year on its final stages of clinical development with a series of multi-national studies including a proposed Phase 3 registration study. In view of this, it was considered timely to trade mark the name, VeyondaTM, ahead of the drug’s anticipated eventual commercial release.
For further information please download PDF attached:
Download this document
